<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042807</url>
  </required_header>
  <id_info>
    <org_study_id>MCS-8-II-TWN</org_study_id>
    <nct_id>NCT02042807</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect of MCS® in Prostate Cancer Prevention</brief_title>
  <acronym>MCS-8</acronym>
  <official_title>A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Ever Bio-Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Ever Bio-Tech Co., Ltd.</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of MCS® compared with placebo in reducing the risk of
      biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative biopsy-detectable prostate cancer rate</measure>
    <time_frame>Week 104 (Month 24)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">702</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCS® 15 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MCS® soft capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCS® 30 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MCS® soft capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS®</intervention_name>
    <arm_group_label>MCS® 15 mg/day</arm_group_label>
    <arm_group_label>MCS® 30 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. high-risk subjects of prostate cancer.

          2. Male subject with age from 50 to 75 years old.

          3. Subject is able to understand and willing to comply with the study procedures and has
             signed the informed consent form (ICF).

        Exclusion Criteria:

          1. Subjects who are or will be taking long-term hormonal agents that may affect the
             normal physiology of sex hormone function.

          2. Subjects with a PSA &gt; 10.0 ng/ml.

          3. Subjects with a history of prostate cancer.

          4. Subject participated in another investigational agent study in the past 30 days or is
             planning to do so during the study period.

          5. Subjects are considered ineligible for the study as judged by the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Health Ever Bio-Tech Co., Ltd.</last_name>
    <phone>+886-2-25788621</phone>
    <email>heb@hebiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Urology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeong-Shiau Pu</last_name>
      <phone>+886 2 23123456</phone>
    </contact>
    <investigator>
      <last_name>Yeong-Shiau Pu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

